CD38 and neoplasm: Preclinical studies and clinical studies have suggested other areas of potential usefulness for JAK inhibitors for treating MM patients (Figure 1) based on its ability to increase the expression of CD38 on MM tumor cells and reduce the risk and severity of IRAEs from bispecific antibody and CAR-T cell therapies while simultaneously augmenting the anti-tumor effects of these immune-based therapies.